TECHNOLOGY-BASED
pharmaceutical company Verseon
has announced that it has
developed a new class of oral,
highly selective, direct thrombin
inhibitors which have demonstrated
reduced risk of major bleeding in
comparison with current novel oral
anticoagulants (NOACs).
The announcement was
presented at the Biotech Showcase
Conference in San Francisco this
week.
The early pre-clinical studies have
indicated that the new compounds
have equivalent or better
therapeutic potential, the company
said, adding that they are still a few
years from marketing approvals.The above article was sent to subscribers in Pharmacy Daily's issue from 14 Jan 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Jan 16
PEAK pharmacy bodies are calling on the Australian Government to extend the new Commonwealth Prac Payment to pharmacy students, citing the challenges of “placement poverty” in unpaid practical placements.
AFT Pharmaceuticals is set to develop a topical treatment for keloid and hypertrophic scarring in partnership with NZ’s Massey Ventures, the commercialisation arm of Massey University, and the Gillies McIndoe Research Institute.
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.